Newland Pharmaceutical Co., Ltd. (SHE:301277)

Market Cap	4.52B -14.1%
Revenue (ttm)	659.54M -13.4%
Net Income	100.78M -42.2%
EPS	0.26 -41.6%
Shares Out	392.08M
PE Ratio	44.75
Forward PE	n/a
Dividend	0.20 (1.73%)
Ex-Dividend Date	Apr 30, 2026

Volume	1,943,941
Average Volume	3,290,859
Open	11.46
Previous Close	11.33
Day's Range	11.44 - 11.68
52-Week Range	10.80 - 18.38
Beta	0.45
RSI	41.79
Earnings Date	Apr 24, 2026

About Newland Pharmaceutical

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 981
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301277

Financial Performance

In 2025, Newland Pharmaceutical's revenue was 672.38 million, a decrease of -7.44% compared to the previous year's 726.44 million. Earnings were 121.25 million, a decrease of -30.17%.